|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Interferon therapy in hepatitis Cleading to chronic type 1 diabetes显示文摘AIM: To review the prevalence,clinical data and course of interferon-associated type 1 diabetes in chronic hepatitis C virus(HCV) infection.METHODS: Search of all interferon(INF)-related type 1diabetes mellitus(T1DM) cases published in the English literature from 1992 to December 2013 according to the key words: chronic hepatitis C infection,diabetes mellitus type 1,insulin dependent diabetes mellitus,and interferon treatment.We found 107 cases and analyzed their clinical and laboratory data and long-term followup.Due to the predominance of cases described in Japanese literature,we analyzed separately cases of Caucasian and Japanese origin.In addition we describe a representative case with HCV who developed INFrelated T1 DM.RESULTS: Our data show that INF treatment increases the risk of developing T1 DM by 10-18 fold compared with the corresponding general population and the median age of onset was 43 years(range: 24-66 years) in Caucasians and 52 years(range: 45-63 years) in Japanese.Most patients developed T1 DM during INF treatment,after a median time-period of 4.2 and 5.7 mo in Caucasian and Japanese groups,respectively.The clinical course was characterized by a fulminant course with abrupt severe hyperglycemia or ketoacidosis,a high titer of anti-islet autoantibodies and almost all patients(105/107) permanently required insulin therapy with a follow-up of up to 4 years.A substantial number of patients had evidence for other autoimmune disorders mainly thyroid diseases(25% and 31% in Caucasian and Japanese groups,respectively).CONCLUSION: INF-associated T1 DM in HCV has a fulminant course,often associated with other autoimmune diseases,and results almost inevitably in permanent insulin therapy requirement. | Taiba Zornitzki Stephen Malnick Lyudmila Lysyy Hilla Knobler | 2015 | World Journal of Gastroenterology2015，21，1： | 17 |
| 2 | Helicobacter pylori : Friend or foe?显示文摘Helicobacter pylori(H. pylori) is a Gram-negative spiral bacterium that is present in nearly half the world's population. It is the major cause of peptic ulcer disease and a recognized cause of gastric carcinoma. In addition, it is linked to non-ulcer dyspepsia, vitamin B12 deficiency, iron-deficient anemia and immune thrombocytopenic purpura. These conditions are indications for testing and treatment according to current guidelines. An additional indication according to the guidelines is 'anyone with a fear of gastric cancer' which results in nearly every infected person being eligible for eradication treatment. There may be beneficial effects of H. pylori in humans, including protection from gastroesophageal reflux disease and esophageal adenocarcinoma. In addition, universal treatment will be extremely expensive(more than $32 billion in the United States), may expose the patients to adverse effects such as anaphylaxis and Clostridium difficile infection, as well as contributing to antibiotic resistance. There may also be an as yet uncertain effect on the fecal microbiome. There is a need for robust clinical data to assist in decision-making regarding treatment of H. pylori infection. | Stephen David Howard Malnick Ehud Melzer Malka Attali Gabriel Duek Jacob Yahav | 2014 | World Journal of Gastroenterology2014，20，27： | 15 |
| 3 | Non-alcoholic fatty liver disease-the heart of the matter显示文摘Non-alcoholic fatty liver disease(NAFLD) is one of the most common forms of chronic liver disease in the Western world. There is a close association with the metabolic syndrome and NAFLD is considered to be the hepatic manifestation of the metabolic syndrome. The components of the metabolic syndrome include hypertension,obesity and insulin resistance which are well established cardiovascular risk factors. The mortality rate of NAFLD patients from myocardial infarction is higher than that in the general United States population and there is also an increased risk of nonfatal cardiovascular events. This article reviews the cardiovascular complications associated with NAFLD. Inorder to provide comprehensive care of NAFLD patients,physicians need to be aware of,and search for,the cardiac morbidity associated with NAFLD. | Haneen Azzam Stephen Malnick | 2015 | World Journal of Hepatology2015，7，10： | 7 |
| 4 | Influence of gut bacteria on development and progression of non-alcoholic fatty liver disease显示文摘The intestine of the human contains a dynamic population of microbes that have a symbiotic relationship with the host. In addition, there is an effect of the intestinal microbiota on metabolism and digestion. Non-alcoholic fatty liver disease(NAFLD) is a common cause worldwideof hepatic pathology and is thought to be the hepatic manifestation of the metabolic syndrome. In this review we examine the effect of the human microbiome on the components and pathogenesis of the metabolic syndrome. We are now on the threshold of therapeutic interventions on the human microbiome in order to effect human disease including NAFLD. | Ali Abdul-Hai Ali Abdallah Stephen DH Malnick | 2015 | World Journal of Hepatology2015，7，12： | 7 |
| 5 | Acute Hepatitis E Virus Infection Presenting as a Prolonged Cholestatic Jaundice显示文摘 | Laura Mechnik Nina Bergman Malka Attali Marc Beergabel Bruce Mosenkis Nadia Sokolowski Stephen Malnick | 2001 | Journal of Clinical Gastroenterology2001，，5： | 2 |
| 6 | Chronic ischaemic bowel disease in the aged-go with the flow显示文摘 | Korotinski S Katz A Malnick SD | | 0，，1： | 1 |
| 7 | The medical complications of obesity 显示文摘 | MALNICK S D KNOBLERH | 2006 | Q J M2006，9，12： | 1 |
| 8 | Pseudomonas paucimobilis,a new species isolated from human clinical specimens,the hospital environment,and other sources显示文摘 | Holmes B Owen RJ Evans A Malnick H Willcox WR | 1977 | Int J Syst Bacteriol1977，27，： | 1 |
| 9 | A case of peritonitis caused by Roseomonas gilardii in a patient undergoing continuous ambulatory peritoneal dialysis 显示文摘 | Sandoe JA Malnick H Loudon KW | 1997 | J Clin Microbiol1997，35，8： | 1 |
| 10 | Chronic ischaemic bowel diseases in the aged-go with the flow显示文摘 | Korotinski S Katz A Malnick SD | 2005 | Age Ageing2005，34，1： | 1 |
| 11 | HCV Hepatitis Associated with Anticardiolipin Antibody and a Cerebrovascular Accident: Response to Interferon Therapy显示文摘 | Stephen D. H. Malnick Yitzhak Abend Ella Evron Zev M. Sthoeger | 1997 | Journal of Clinical Gastroenterology1997，，1： | 1 |
| 12 | Distribution of genes encoding putative transmissibility factors among epidemic and nonepidemie strains of Burkholderia cepacia from cystic fibrosis patients in the United Kingdom显示文摘 | Clode FE Kaufmann ME Malnick H | 2000 | J Clin Microbiol2000，38，5： | 1 |
| 13 | A case of peritonitis caused by Roseomonas gilardii in a patient undergoing continuous ambulatory perioneal dialysis显示文摘 | Sandoe JAT Malnick H Loudon KW | 1997 | J Clin Microbiol1997，35，8： | 1 |
| 14 | pylori infetion显示文摘 | Malnick S d Goland S Kaftoury A Evaluation of carotid arterial Plaques afore endartectomy for H | 1999 | Am J Cardiol1999，83，： | 1 |
| 15 | Non-alcoholic fatty liver: a common manifestation of a metabolic disorder 显示文摘 | Malnick SD Beergabel M Knobler H | 2003 | QJM2003，96，10： | 1 |
| 16 | Distribution of genes encoding putative transmissibility factors among epidemic and nonepidemic strains of Burkholderia cepacia from cystic fibrosis patients in the United Kingdom 显示文摘 | Clode F E Kaufmann M E Malnick H | 2000 | J Clin Micmbiol2000，38，5： | 1 |
| 17 | The medicalcomplications of obesity 显示文摘 | MALNICK S D KNOBLERH | 2006 | QJM2006，9，12： | 1 |
| 18 | The Medical Complications of Obesi- ty 显示文摘 | Malnick SDH Knobler H | 2006 | Q J Med2006，99，： | 1 |
| 19 | The medical complications of obe- sity 显示文摘 | Malnick SD Knobler H | 2006 | QJM2006，99，9： | 1 |
| 20 | Acute hepatitis E virus infection presenting as a prolonged cholestatic jaundice 显示文摘 | Mechnik L Bergman N Attali M Beergabel M Mosenkis B Sokolowski N Malnick S | 2001 | J Clin Gastroenterol2001，33，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员